Latest News

Thursday, August 17, 2017 | Medical Studies,Retina

First Patient Enrolled in USH2A Natural History Study

The first patient has been enrolled in a 4-year natural history study of people with mutations in the USH2A gene which are the leading cause of the combined vision and hearing loss associated with Ush…

Read the full story

Thursday, August 17, 2017 | Conferences, Topcon Medical Systems

Topcon Corporation Announces 2nd International Swept Source OCT and Angiography Conference

Topcon announced the 2nd annual International Swept Source OCT & Angiography Conference will take place in Paris on February 16 & 17, 2018 at Le Méridien Etoile. Sponsored by Topcon …

Read the full story

Thursday, August 17, 2017 | Medical Studies

Corneal Patch Grafts Thin After Aqueous Drainage Device Placement

Gradual thinning of gamma-irradiated sterile cornea (GISC) patch grafts covering glaucoma-treating aqueous drainage devices (ADDs) suggests ensuing tube exposure, according to researchers in the Unite…

Read the full story

Wednesday, August 16, 2017 | Miscellaneous, Bausch+Lomb, Valeant

FDA Says Inspection Issues at Bausch + Lomb Manufacturing Plant in Tampa facility are Being Resolved

Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa. With this confirmation,…

Read the full story

Wednesday, August 16, 2017 | Miscellaneous

Two Senators Urge Federal Trade Commission to Finalize Changes to Contact Lens Rule

Senators Orrin Hatch (R-Utah) and Richard Blumenthal (D-Conn.) are joining the industry fray over proposed changes to the Contact Lens Rule. The senators sent a letter earlier this week to Maureen Ohl…

Read the full story

Wednesday, August 16, 2017 | Medical Studies, ThromboGenics

New ThromboGenics’ Ocriplasmin Clinical and Health Economic Data Presented at ASRS

ThromboGenics NV announced that further ocriplasmin clinical and health economic data was presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Boston…

Read the full story

Wednesday, August 16, 2017 | Retina, AMD, Opthea

New Anti-VEGF Drug Promising for Wet Macular Degeneration

A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular degeneration, new re…

Read the full story

Tuesday, August 15, 2017 | Dry Eye, Shire

Shire Announces Submission of Lifitegrast Marketing Authorization Application for Treatment of Dry Eye Disease in Europe

Shire announced that it has submitted a Marketing Authorization Application in the UK for lifitegrast for the treatment of dry eye disease. The application, submitted on August 7, 2017, has been valid…

Read the full story

Tuesday, August 15, 2017 | Medical Studies, Ellex

Ellex Announces Release of Study Detailing Safety and Efficacy of YAG Laser Floater Removal

Ellex Medical Lasers announced the release of a study evaluating the safety and efficacy of YAG laser vitreolysis for symptomatic Weiss Ring floater patients in the peer-reviewed journal, Journal of t…

Read the full story

Tuesday, August 15, 2017 | Medical Studies,Retina

UofL Researchers Discover Procedure to Regenerate Dormant Cone Cells, Potentially to Improve Vision in Retinitis Pigmentosa

Researchers at the University of Louisville have discovered a way to revitalize cone receptors that have deteriorated as a result of retinitis pigmentosa (RP). Working with animal models, Henry J. Kap…

Read the full story

Tuesday, August 15, 2017 | Medical Studies

Special Safety Edition: 2017 Great American Eclipse

On August 21, 2017, North America will witness a rare total solar eclipse as the moon passes between the sun and the Earth, blocking daylight for several minutes. The last eclipse of this magnitude wa…

Read the full story

Tuesday, August 15, 2017 | Medical Studies,Retina

Real-World Anti-VEGF Results Fall Short in Macular Edema

Real-world patients with diabetic macular edema treated with anti -- vascular endothelial growth factor (VEGF) do not do as well as similar patients in clinical trials, according to an analysis of med…

Read the full story

Monday, August 14, 2017 | Management/Leadership, SightLife Surgical

SightLife Board of Directors Appoints Claire Bonilla as CEO

The board of directors for SightLife has appointed Claire Bonilla as Chief Executive Officer, effective August 21, 2017. Ms. Bonila, who has served as SightLife’s Chief Global Officer …

Read the full story

Monday, August 14, 2017 | Retina, AMD, BioTime

BioTime Announces $2 Million Grant for Further Development of OpRegen for Dry-AMD

BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA). The grant provides funding for the continu…

Read the full story

Monday, August 14, 2017 | Clinical Trials,Retina, AMD, Ophthotech

Ophthotech's Fovista Fails Third Phase 3 Trial in Wet AMD

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase 3 clinical trial investigating the superiority of Fovis…

Read the full story
Load More
 Stock Price  Change 
 ADVM $2.55  2.00% 
 Aerie Pharmaceuticals, Inc. $55.10  5.56% 
 Akorn, Inc. $33.13  -0.51% 
 Alimera Sciences, Inc. $1.43  -0.69% 
 Allergan $227.07  -0.40% 
 Applied Genetic Technologies $5.20  1.96% 
 Bayer $127.15  0.07% 
 Can-Fite Biopharma $1.68  0.60% 
 Clearside Biomedical $7.24  2.26% 
 Cooper Companies, Inc. $245.08  0.21% 
 Eleven Biotherapeutics $1.10  -13.39% 
 Escalon Medical Corp. $0.10  -0.10% 
 Glaukos $37.91  0.26% 
 Imprimis Pharmaceuticals, Inc. $2.25  -2.17% 
 Inotek Pharmaceuticals $0.98  -0.60% 
 IRIDEX Corporation $8.37  -0.12% 
 Johnson & Johnson $133.24  -0.69% 
 Merck & Company, Inc. $62.47  -0.37% 
 NovaBay Pharmaceuticals, Inc. $0.14  -6.67% 
 Novartis AG Common Stock $83.73  -0.76% 
 Ocular Therapeutix $5.86  1.03% 
 Ophthotech Corporation $2.79  -0.36% 
 Regeneron $466.56  -0.42% 
 Roche $31.67  0.41% 
 Second Sight Medical Products $0.99  -1.00% 
 Shire $149.53  0.73% 
 STAAR Surgical Company $11.82  -0.67% 
 TearLab Corporation $1.70  7.59% 
 Valeant Pharmaceuticals $14.63  3.36% 
 Xoma $7.54  1.75%